Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; BIIB061; BIIB054; BIIB067, and BIIB068.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Exchange: NASDAQ
- Symbol: BIIB
- CUSIP: 09062X10
- Previous Close: $285.13
- 50 Day Moving Average: $280.83
- 200 Day Moving Average: $296.10
- 52-Week Range: $215,951,000.00 - $223.02
- Trailing P/E Ratio: 16.84
- Foreward P/E Ratio: 12.66
- P/E Growth: 2.16
- Market Cap: $61.57B
- Outstanding Shares: 215,951,000
- Beta: 0.72
- Net Margins: 32.34%
- Return on Equity: 38.48%
- Return on Assets: 20.29%
Companies Related to Biogen:
- Debt-to-Equity Ratio: 0.54%
- Current Ratio: 2.55%
- Quick Ratio: 2.26%
What is Biogen's stock symbol?
Biogen trades on the NASDAQ under the ticker symbol "BIIB."
Where is Biogen's stock going? Where will Biogen's stock price be in 2017?
22 equities research analysts have issued 12-month target prices for Biogen's shares. Their predictions range from $285.00 to $386.00. On average, they anticipate Biogen's stock price to reach $334.00 in the next year.
When will Biogen announce their earnings?
Biogen is scheduled to release their next quarterly earnings announcement on Wednesday, April, 19th 2017.
What are analysts saying about Biogen stock?
Here are some recent quotes from research analysts about Biogen stock:
Jefferies Group LLC analysts commented, "This morning BIIB announced a settlement with FWP around Tecfidera IP. While we believe Street expectations were generally balanced going into the 3/17 decision (and we had assumed 50/50 prob. BIIB would be successful), commercial and some IPR risk remains, and recent focus has been more on Spinraza launch and Alzheimer’s, the terms look reasonable to us and help reduce an overhang." (1/18/2017)
Cantor Fitzgerald analysts commented, "Date and time of first dissemination: January 06, 2017, 09:14 ET Date and time of production: January 06, 2017, 09:14 ET Target Price / Valuation Methodology: Regeneron Pharmaceuticals – REGN Our $450 price target for Regeneron shares is based on a discounted cash flow (DCF) valuation. Risks to achieving Target Price / Valuation: Regeneron Pharmaceuticals – REGN Regeneron’s revenues and/or EPS may fall below our estimates, resulting in downside to our target price. Specifically, US Eylea revenues from diabetic macular edema may be lower than expected due to competition from laser procedures, and a very short dosing period for Eylea." (1/6/2017)
Cowen and Company analysts commented, "Third party sources indicate Spinraza has been priced at a WAC of $125K/injection." (12/30/2016)
According to Zacks Investment Research, "Biogen’s multiple sclerosis (MS) franchise should continue driving the top-line while new products should do well. Cost cutting efforts should help the company achieve its guidance. Biogen also has some pipeline events lined up and the company continues to work on strengthening its product portfolio. Moreover, the upcoming spin-off of the hemophilia business will allow Biogen to focus on the neurology segment, which is its key area of expertise. However, Biogen does have some challenges in store. Although the company holds a strong position in the MS market, the emergence of additional PML cases for Tecfidera would weigh heavily on the stock as would pipeline setbacks. Biogen’s interferon products are also under pressure with patients continuing to shift to oral therapies. The investigation into the company’s sales and promotion practices is also concerning." (8/12/2016)
Credit Suisse Group analysts commented, "We continue to think long term the base business faces headwinds, but in the near term we think products are defending better through a mix of steadier volumes than expected and price increases. Coupled with strong expense management we think Biogen is positioned well on 2016 earnings and we are forecasting a top and bottom line beat for the full year 2016." (7/22/2016)
Who owns Biogen stock?
Biogen's stock is owned by a number of of retail and institutional investors. Top institutional investors include State Street Corp (4.33%), FMR LLC (3.80%), Sands Capital Management LLC (1.19%), Viking Global Investors LP (0.89%), Franklin Resources Inc. (0.83%) and Orbimed Advisors LLC (0.59%). Company insiders that own Biogen stock include Adam Koppel, Adriana Karaboutis, Alexander J Denner, Alfred Sandrock, Caroline Dorsa, Douglas E Williams, Eric K Rowinsky, George A Scangos, John Cox, Robert W Pangia and Stelios Papadopoulos.
Who sold Biogen stock? Who is selling Biogen stock?
Biogen's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Viking Global Investors LP, Sands Capital Management LLC, Tudor Investment Corp Et Al, Franklin Resources Inc., Numeric Investors LLC, AMF Pensionsforsakring AB and I.G. Investment Management LTD.. Company insiders that have sold Biogen stock in the last year include Adam Koppel, Adriana Karaboutis, Caroline Dorsa, George A Scangos and Robert W Pangia.
Who bought Biogen stock? Who is buying Biogen stock?
Biogen's stock was purchased by a variety of institutional investors in the last quarter, including DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main, Renaissance Technologies LLC, Discovery Capital Management LLC CT, Sarissa Capital Management LP, Asset Management One Co. Ltd., State Street Corp, Russell Investments Group Ltd. and Fred Alger Management Inc.. Company insiders that have bought Biogen stock in the last two years include Alexander J Denner and Stelios Papadopoulos.
How do I buy Biogen stock?
Shares of Biogen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Biogen stock cost?
One share of Biogen stock can currently be purchased for approximately $285.13.